QRG Capital Management Inc. Acquires 64,689 Shares of Bristol Myers Squibb Company $BMY

QRG Capital Management Inc. lifted its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 22.2% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 355,896 shares of the biopharmaceutical company’s stock after purchasing an additional 64,689 shares during the quarter. QRG Capital Management Inc.’s holdings in Bristol Myers Squibb were worth $21,585,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the stock. Swiss RE Ltd. acquired a new position in Bristol Myers Squibb during the 4th quarter worth $25,000. Darwin Wealth Management LLC bought a new stake in Bristol Myers Squibb during the 2nd quarter worth about $25,000. Physician Wealth Advisors Inc. grew its position in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 202 shares during the period. Bayban acquired a new position in Bristol Myers Squibb in the fourth quarter valued at approximately $31,000. Finally, EQ Wealth Advisors LLC acquired a new stake in Bristol Myers Squibb during the 4th quarter worth $32,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Trading Down 0.1%

NYSE BMY opened at $58.05 on Friday. The stock has a market capitalization of $118.54 billion, a price-to-earnings ratio of 16.31, a PEG ratio of 0.17 and a beta of 0.23. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The stock’s 50 day moving average price is $56.90 and its two-hundred day moving average price is $57.49. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. The business had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts anticipate that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. Bristol Myers Squibb’s payout ratio is 70.79%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Cantor Fitzgerald upped their price objective on Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a report on Wednesday, April 8th. HSBC increased their target price on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Weiss Ratings reissued a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Monday, March 23rd. Finally, Bank of America dropped their price target on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a research report on Thursday, April 9th. Eight equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus price target of $61.31.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.